Whether Canafenib/Encofenib (Betavir) can be used to treat colorectal cancer and analysis of its efficacy

Canafenib (Encorafenib) is an oral small molecule BRAF inhibitor that mainly targets BRAF V600 mutations. Although it initially showed significant efficacy in melanoma patients, as clinical studies progressed, Encorafenib was also used in patients with BRAF V600E-mutated advanced or metastatic colorectal cancer (mCRC). For patients with colorectal cancer who carry this specific mutation, traditional chemotherapy has limited efficacy, and treatments targeting the BRAF pathway provide new treatment options.

Clinical studies have shown that Encorafenib has limited efficacy as a single drug in colorectal cancer, and some patients only show stable disease or slight shrinkage. Therefore, in practical applications, other targeted drugs, such as EGFR monoclonal antibodies (Cetuximab), are usually combined to improve the therapeutic effect. This combination regimen has been proven by clinical trials to significantly extend progression-free survival (PFS) and overall survival (OS), and improve the quality of life of some patients.

In terms of efficacy evaluation, the regimen of Encorafenib combined with EGFR inhibitors usually requires imaging and biomarker monitoring to observe changes in tumor volume, CEA levels and disease stability. Research shows that forBRAF For patients with V600Emutated metastatic colorectal cancer, the overall response rate (ORR) of this combination regimen can reach 20%~25 %, the disease control rate (DCR) can reach 70% or more, which is significantly better than traditional chemotherapy regimens.

In general, the application of canafenib/encofenib in colorectal cancer is mainly targeted at patients with BRAF V600E mutations. The efficacy of single drug is limited, but better clinical effects can be obtained in combination with EGFR inhibitors. Patients need to be followed up regularly during use to monitor tumor changes and side effects, such as rash, fatigue, abnormal liver function, etc. Through individualized course adjustment and scientific management,EncorafenibCombination therapy provides a new treatment option for this high-risk patient group and improves prognosis to a certain extent.

Reference materials:https://www.drugs.com/